ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer

ConditionRecurrent or Metastatic Cervical Cancer

Trial statusNot yet recruiting

Trial phasePhase 1, Phase 2

Trial typeInterventional

Biological sexFemale

Age18+

SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University

About this trial

This is a single-arm, multicenter, phase II study designed to evaluate the efficacy and safety of MRG003, an anti-EGFR antibody-drug conjugate, in combination with QL1706, a PD-1/CTLA-4 bispecific antibody, in patients with recurrent or metastatic cervical cancer who have failed prior platinum-based therapy.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

Treatment

Treatment groups

41 Participants

are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators

Second Affiliated Hospital, School of Medicine, Zhejiang University

Lead sponsor

Source ClinicalTrials.gov